Logo

CALC

CalciMedica, Inc.

CALC

CalciMedica, Inc. • NASDAQ
$4.27 ▲ 4.15% (+0.17)
Market Cap $61.53 M
52w High $4.50
52w Low $1.42
Dividend Yield 0%
P/E -2.64
Volume 33.34K
Outstanding Shares 14.41M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $5.618M ▼ $-7.804M ▼ 0% $-0.52 ▼ $-7.478M ▼
Q2-2025 $0 $6.621M ▲ $-5.956M ▼ 0% $-0.4 ▼ $-5.618M ▼
Q1-2025 $0 $6.497M ▲ $-5.042M ▼ 0% $-0.36 ▼ $-4.58M ▼
Q4-2024 $0 $6.158M ▲ $-4.258M ▲ 0% $-0.33 ▲ $-4.244M ▲
Q3-2024 $0 $5.736M $-5.618M 0% $-0.5 $-5.721M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $14.084M ▼ $14.913M ▼ $15.181M ▲ $-268K ▼
Q2-2025 $17.957M ▼ $19.08M ▼ $12.977M ▼ $6.103M ▼
Q1-2025 $24.625M ▲ $25.347M ▲ $14.459M ▲ $10.888M ▼
Q4-2024 $18.669M ▲ $19.794M ▲ $5.384M ▼ $14.41M ▲
Q3-2024 $14.603M $16.212M $7.182M $9.03M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.804M ▼ $-4.778M ▲ $3.512M ▲ $818K ▲ $-448K ▲ $-4.786M ▲
Q2-2025 $-5.956M ▼ $-6.67M ▼ $134K ▲ $-102K ▼ $-6.638M ▼ $-6.675M ▼
Q1-2025 $-5.042M ▼ $-4.878M ▲ $-1.243M ▲ $10.742M ▲ $4.621M ▲ $-4.887M ▲
Q4-2024 $-4.258M ▲ $-4.972M ▼ $-5.167M ▼ $8.922M ▲ $-1.217M ▼ $-4.974M ▼
Q3-2024 $-5.618M $-4.667M $8.747M $16K $4.095M $-4.673M

Five-Year Company Overview

Income Statement

Income Statement CalciMedica is a classic early-stage biotech: it has essentially no product revenue yet and runs a consistent operating loss driven by research and development and corporate costs. Losses have been steady over several years rather than exploding, which suggests some cost control, but the business is still firmly in the investment phase with no commercial income to offset spending. Per‑share losses look large, but they are also affected by past share structure changes, so the headline figures can appear worse than the underlying cost trend.

Balance Sheet

Balance Sheet The balance sheet is very small and relatively simple. The company holds a modest cash balance and only limited other assets, with little to no financial debt, which reduces interest burden but also highlights a constrained resource base. Shareholders’ equity has moved from negative to slightly positive territory, indicating some recapitalization or fresh equity funding. Overall, the balance sheet underlines that CalciMedica remains a lean, development-stage company with limited buffers and an ongoing need for external capital as it advances its pipeline.

Cash Flow

Cash Flow Cash flows are negative and closely track the company’s operating losses, as you would expect for a pre-revenue biotech. Operating cash outflows have been fairly consistent over time, showing a steady pace of spending on trials and overhead rather than sharp spikes. Capital spending on equipment or facilities is negligible, so virtually all cash use is tied to R&D and operations. This pattern means the company’s ability to keep funding its programs depends heavily on raising additional cash through financings, partnerships, or other non-operating sources.

Competitive Edge

Competitive Edge CalciMedica operates in a highly competitive broader inflammatory disease space, but it is focused on a relatively specialized mechanism—CRAC channel inhibition—where there are few direct competitors at a similar clinical stage. Its lead candidate, targeting severe inflammatory conditions with no approved disease‑modifying treatments, gives it a potential first‑mover edge if results continue to be positive and regulators are supportive. At the same time, the company is small relative to large pharma players, so it faces the usual risks: limited resources for large trials and commercialization, potential for competing approaches to catch up, and heavy reliance on a narrow set of indications and one principal asset.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. CalciMedica is advancing a differentiated mechanism that aims both to calm excessive immune responses and protect tissues from damage, which is scientifically compelling for acute inflammatory diseases. The lead drug, Auxora, has generated encouraging mid‑stage data in high‑need hospital settings, and the company is preparing for pivotal work in acute pancreatitis while also exploring acute kidney injury. Beyond this, it is investing in oral versions for chronic diseases and using AI tools to extract more insight from clinical data. The R&D strategy is focused but still concentrated in a single platform, which magnifies both the upside if it works and the downside if trials disappoint.

Summary

CalciMedica is an early-stage biotech with no current product revenue, steady but meaningful losses, and a small balance sheet supported by modest cash and minimal debt. Its financial profile is typical of a clinical‑stage company that depends on ongoing external funding to progress its pipeline. Strategically, the company is built around a novel CRAC channel inhibition approach, with a lead candidate that targets serious inflammatory conditions lacking effective treatments. This gives it a potentially valuable niche and a degree of scientific differentiation, but also concentrates risk in a limited set of programs and indications. Future outcomes will hinge on clinical trial execution, regulatory feedback on pivotal studies, and the company’s ability to maintain funding through the development cycle.

NEWS

November 12, 2025 · 7:01 AM UTC

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Read more

November 12, 2025 · 7:00 AM UTC

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Read more

November 10, 2025 · 7:00 AM UTC

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Read more

October 14, 2025 · 7:00 AM UTC

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Read more

September 2, 2025 · 7:00 AM UTC

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Read more